
Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.
The company’s lead drug candidate, BPL-003, is under development for treatment-resistant depression.